OneSource Specialty Pharma Limited has reported its audited financial results for the quarter and financial year ended March 31, 2026. The company announced a strong sequential recovery in Q4FY26, driven by the commencement of commercial shipments for drug device combinations and the launch of generic Semaglutide in India.

Financial Performance

For the fourth quarter, revenue stood at INR4,282 million, reflecting a 47% sequential growth. On a full-year basis, the company reported INR14,216 million in revenue, a 2% decline year-on-year attributed to delayed approvals in the previous quarter.

Profitability saw a sharp rebound in Q4. EBITDA was reported at INR919 million, expanding by more than 5x sequentially with margins increasing by 1,550 basis points. Adjusted Profit After Tax (PAT) for the quarter was INR390 million compared to a loss in the previous quarter. For the full year FY '26, adjusted PAT stood at INR739 million.

Operational Highlights

The company confirmed that its new manufacturing line is currently undergoing qualification and is expected to be available for commercialization in Q2FY27. Management noted that the current line is fully committed. The biologics business continues to generate significant interest, with the funnel expanding 4x versus the previous year.

Strategic Guidance

Management reaffirmed its long-term guidance for FY '28, targeting US$400 million in organic revenue with approximately 40% EBITDA margins. The company also announced the deferral of a previously announced scheme to acquire the injectables business of Steriscience and Brooks, citing valuation concerns and a focus on delivering the FY '28 guidance.

OneSource Specialty Pharma Limited has secured in-principle approval from the Government of Karnataka for the expansion of its Unit II facility, under the Karnataka Industrial Policy (KIP) 2025–30. The approval pertains to incentives and concessions associated with the company's proposed investment in expanding its manufacturing infrastructure, marking a notable development in its growth trajectory.

Approval Details

The key details of the government approval are outlined below:

Facility and Expansion Scope

The expansion pertains to Unit II, the company's flagship facility, situated at Obadenahalli, 2nd Phase, KIADB Industrial Area, Doddaballapur Taluk, Bengaluru Rural District. The proposed expansion is aimed at enhancing manufacturing capacities to better service the company's global partners. Unit II holds strategic importance within the company's operational framework, and this expansion is described as a significant step in the company's broader growth strategy.

Regulatory Disclosure

The development was disclosed by OneSource Specialty Pharma under Regulation 30, as communicated to BSE Limited and the National Stock Exchange of India Limited on May 16, 2026. The disclosure was signed by Trisha A, Company Secretary and Compliance Officer, Membership Number A47635.